Conditions: Diabetes Mellitus Type 2
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 262
Healthy volunteers: no

Brief summary:
To study once weekly injections of LY2189265 compared to placebo on blood glucose by measuring glycosylated hemoglobin (HbA1c) change from baseline after 16 weeks in overweight Type 2 Diabetes Mellitus participants.

Detailed description:

Arms:
arm 1: LY2189265: 1.0 milligram (mg), subcutaneous (SC) injection, once weekly (QW) for 4 weeks; followed by 2.0 mg, SC injection, QW for 12 weeks arm 2: LY2189265: 1.0 mg, subcutaneous (SC) injection, once weekly (QW) for 16 weeks arm 3: LY2189265: 0.5 milligram (mg), subcutaneous (SC) injection, once weekly (QW) for 4 weeks; followed by 1.0 mg, SC injection, QW for 12 weeks arm 4: Placebo: subcutaneous (SC) injection, once weekly (QW) for 16 weeks

Interventions: intervention 1: LY2189265 intervention 2: Placebo
Intervention descriptions: intervention 1: None intervention 2: None

Protocol document: